FDA Investigates Potential Cancer Risks Linked to Novartis Gene Therapy Zolgensma
The FDA is investigating Novartis’ Zolgensma gene therapy following reports of serious cancer risks, potentially impacting the product’s regulatory status…

The U.S. Food and Drug Administration (FDA) has initiated a formal investigation into Novartis’ gene therapy, Zolgensma, following reports of serious cancer risks associated with the treatment. Zolgensma is a one-time gene therapy indicated for the treatment of pediatric patients under two years of age with spinal muscular atrophy (SMA).
The regulatory inquiry focuses on identifying a causal link between the administration of the therapy and the development of malignancies in patients. This investigation follows internal and external reports indicating potential safety signals that warrant a comprehensive review of the product's clinical profile.
For institutional stakeholders, this development introduces significant regulatory and reputational risk for the manufacturer. The outcome of the FDA investigation could lead to updated safety labeling, the implementation of more stringent monitoring requirements, or, in extreme scenarios, a suspension of distribution if the risk-benefit profile is deemed unfavorable.
Drug Administration
Investors and healthcare providers should monitor for upcoming regulatory communications regarding the scope of the investigation and any potential impact on the therapy's current market authorization. The FDA is expected to evaluate long-term patient data to determine if the observed cancer cases represent a systemic safety issue inherent to the therapy's delivery mechanism or isolated incidents.
This investigation underscores the ongoing regulatory scrutiny surrounding advanced gene therapies and the challenges of monitoring long-term safety outcomes in pediatric populations. Future updates from the agency will be critical in assessing the long-term viability of the treatment and the potential for broader implications within the gene therapy sector.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Adults 50 to 64 reach 7.5% heavy-drinking rate
- Dinch exposure correlates with 27-gram lower birth weight
- Pope Leo XIV faces lung cancer diagnosis after lobe removal
- Guinea fowl avoid 23% energy cost after early leg loading
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

